

TRANSFORMATION THROUGH INNOVATION

LIFE SCIENCES / EXECUTIVE MANAGEMENT

Datasheet



In today's Life Science industry, 25% of a company's market value is directly attributable to reputation, which hinges on many indicators including productivity, innovation, quality, financial performance, brand equity, competitiveness, corporate social responsibility, safety and security. (Deloitte, 2014 Global Survey on Reputation Risk)

In the face of flat or declining R&D productivity, continuing patent expirations, increasing competition, growing globalization and intensifying compliance pressure, Life Science companies remain committed to building and maintaining strong reputations today with a clear focus on:

- Selecting the right strategy to drive productivity
- Driving innovation to deliver superior results to patients, doctors and healthcare providers
- Leveraging global presence to accelerate growth
- Building successful industry partnerships
- Providing industry-leading return of capital to shareholders

A trusted, strategic informatics partner can improve innovation productivity and reduce reputation risk for Life Science companies by engaging with them to:

- Unleash collaboration and open innovation across the organization


- Harmonize data, models and knowledge across functional domains
- Ensure the highest standards of quality and compliance across the product lifecycle

Transitioning to a digital enterprise foundation is the first step in building a shared informatics environment where internal and external partners can collaborate effectively to turn research breakthroughs into successful new therapeutics.

Standardizing on an integrated digital informatics solution from Dassault Systèmes BIOVIA® can turn your Life Science vision into action and results by helping organizations move to data-driven deep learning made possible by an end-to-end, model-driven culture and shared knowledgebase that improves collaboration and accelerates productivity in advancing high quality candidates to market.

Searching for innovation and growth

Companies continue to look for opportunities to replenish pipelines, foster innovation, and collaboration across the health care value chain, and seek revenue growth.



Use of generics



Loss of revenue from patent expiry





R&D productivity has been in decline, but recent trends indicate a turnaround may be under way:

- ▶ NPV of sector's R&D pipeline surging
- ▶ NME approvals rising
- ▶ Phase III approvals increasing (only bringing the most promising drugs to this stage)
- ▶ Restructuring R&D to focus on most promising areas
- ▶ Government investment from many countries in sector R&D efforts
- ▶ Specialty pharma could see growth surge

\$700 billion

M&A transactions in first half of 2014, surpassing entirety of 2013 and nearing totals of mega-merger years 2008 and 2010.

© 2014, Deloitte Touche Tohmatsu Limited

INDUSTRY SOLUTION AND VALUE

Digital scientific solutions from BIOVIA can position a Life Science organization as an industry leader capable of innovating and accelerating a rich pipeline of product candidates, while also ensuring the highest standards of quality and compliance. By improving end-to-end visibility into predictive outcomes, eliminating barriers to collaboration and leveraging predictive, data-driven decisions, organizations can achieve a more integrated and holistic research experience that transforms biopharmaceutical research, development, quality and manufacturing.

Life Science organizations report up to 50% gains in efficiency and throughput, as well as higher quality results, when leveraging integrated solutions that make scientific information more readily available across functional domains.

Reported at BIOVIA User Group Meeting

Life Science organizations can leapfrog the competition by 4-7 years and take the lead in developing high growth, innovative treatments by strategically partnering with BIOVIA to:

- Reduce risk of late-stage attrition
- Accelerate pipeline through better science and enhanced cross-functional collaboration
- Unify intellectual property protection efforts
- Harmonize information, modeling/simulation and knowledge
- Achieve end-to-end innovation productivity
- Ensure quality and regulatory compliance through data security, integrity and traceability

WHY DASSAULT SYSTEMES BIOVIA?

The process of creating successful medicines today requires new ways of "connecting the dots" to the patient from initial project conception and discovery through development, registration and commercialization of therapeutics. Dassault Systèmes BIOVIA understands this challenge and is committed to partnering with Life Science companies to advance the pace of drug development and commercialization.

Bring your company's enterprise vision into sharper focus by entering into a business partnership and executive commitment with Dassault Systèmes BIOVIA. The goal will be to achieve a strategic set of objectives with the aim of achieving significant, mutually-agreed transformational business results for your company.

To learn more, visit accelrys.com.

Our 3DEXPERIENCE® platform powers our brand applications, serving 12 industries, and provides a rich portfolio of industry solution experiences.

Dassault Systèmes, the 3DEXPERIENCE® Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes' collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 190,000 customers of all sizes in all industries in more than 140 countries. For more information, visit www.3ds.com.

